Answers are grounded in this paper and cite their sources.
Syndromic molecular panels offer a rapid approach to assessing a broad collection of pathogens; however, they come with a significant cost to both patients and healthcare systems. Customizable and reflexive syndromic panels offer an opportunity to harness the diagnostic capabilities of syndromic panels, with the potential to reduce cost or increase diagnostic yield. A total of 300 samples from patients with symptoms of an upper respiratory tract infection (URTI) that received inpatient standard of care testing (BioFire ® RP2.1) were tested with the LIAISON PLEX ® Respiratory Flex Assay. To assess seasonal differences, samples were collected in two cohorts covering a period of low influenza-like illness (ILI) (April 2024-June 2024) and elevated ILI (January 2025-March 2025). Following testing, pathogen prevalence was used to retrospectively design panels to maximize diagnostic yield and clinical utility. A 7-target base panel had a diagnostic yield of 80.4% during the low ILI period and 82.5% during the elevated ILI period, as compared to the standard of care syndromic panel. Retrospective application of a base 7-target panel with automatic reflex to full panel would have potentially reduced full-panel usage by 27%. Comparison of diagnostic yield to standard of care outpatient testing (four-target SARS-CoV-2, Influenza A/B, and RSV) demonstrated an increased chance of a diagnosis during both low ILI (80.5% vs 2%) and elevated ILI (82.5% vs 42.1%). Customizable and reflexive panel design has the potential to increase diagnostic yield while reducing duplicative testing and associated costs.
No takes yet. Share an insight, caveat, or question.
Pike et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: